Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica

被引:62
|
作者
Narvaez, Javier [1 ]
Estrada, Paula [1 ]
Lopez-Vives, Laura [1 ]
Ricse, Milagros [1 ]
Zacarias, Andrea [1 ]
Heredia, Sergi
Gomez-Vaquero, Carmen [1 ]
Nolla, Joan M. [1 ]
机构
[1] Hosp Univ Bellvitge IDIBELL, Dept Rheumatol Planta 10 2, Feixa Llarga S-N, Barcelona, Spain
关键词
Giant cell arteritis; Polymyalgia rheumatica; Ischemic complications; TERM FOLLOW-UP; TEMPORAL ARTERITIS; DUPLEX ULTRASONOGRAPHY; DIAGNOSIS; EPIDEMIOLOGY; PATHOGENESIS; INVOLVEMENT; FEATURES; THERAPY; SERIES;
D O I
10.1016/j.semarthrit.2015.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the frequency and type of giant cell attends (GCA)-related ischemic complications in a series of patients with GCA who, for a substantial period of time (i.e., at least 3 mo), lacked vascular symptoms and presented with apparently isolated polymyalgia rheumatica (PMR). Methods: Retrospective follow-up study of an unselected population of 167 patients with GCA diagnosed from 1985 to 2014. Results: In all, 18 patients (11%) developed GCA on a background of a prior history of PMR. They were diagnosed as having isolated PMR because they did not have clinical evidence of GCA at diagnosis and exhibited a prompt and complete response to low-dose steroid therapy. However, during the course of treatment. 17 patients later experienced an arteritic relapse with the development of typical craniofacial symptoms, and one patient developed signs of upper extremity vascular insufficiency, resulting in the diagnosis of large-vessel GCA. The median time to GCA diagnosis from the initiation of low-dose steroid therapy was 9 14.4 mo (range: 3-39). At the time of GCA diagnosis, severe ischemic complications were observed in 50% (9/18) of the patients. Of these patients 22% (4/18) were considered to have "true" occlusive disease (i.e., permanent visual loss, stroke, and/or limb claudication). Late inflammation of the aorta and its branches occurred in 4 (22%) of the patients during long-term follow-up. Conclusion: Patients with GCA presenting with apparently isolated PMR have a significant risk of developing transient or permanent disease -related ischemic complications; these complications occurred in 50% of the cases. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 50 条
  • [1] Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
    Ramon, Andre
    Greigert, Helene
    Ornetti, Paul
    Maillefert, Jean-Francis
    Bonnotte, Bernard
    Samson, Maxime
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
  • [2] Giant Cell Arteritis and Polymyalgia Rheumatica: an Update
    Gonzalez-Gay, Miguel A.
    Pina, Trinitario
    CURRENT RHEUMATOLOGY REPORTS, 2015, 17 (02)
  • [3] Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica
    De Miguel, Eugenio
    Macchioni, Pierluigi
    Conticini, Edoardo
    Campochiaro, Corrado
    Karalilova, Rositsa
    Monti, Sara
    Ponte, Cristina
    Klinowski, Giulia
    Monjo-Henry, Irene
    Falsetti, Paolo
    Batalov, Zguro
    Tomelleri, Alessandro
    Hocevar, Alojzija
    RHEUMATOLOGY, 2024, 63 (01) : 158 - 164
  • [4] Prevalence of synovitis in patients with polymyalgia rheumatica and/or giant cell arteritis
    Devauchelle, V
    Saraux, A
    Youinou, P
    LeGoff, P
    REVUE DU RHUMATISME, 1997, 64 (10): : 594 - 595
  • [5] Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica
    El Chami, Sarah
    Springer, Jason M.
    MEDICAL CLINICS OF NORTH AMERICA, 2021, 105 (02) : 311 - 324
  • [6] Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica
    El Chami, Sarah
    Springer, Jason M.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2022, 48 (02) : 493 - 506
  • [7] Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
    Matteson, Eric L.
    Buttgereit, Frank
    Dejaco, Christian
    Dasgupta, Bhaskar
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (01) : 75 - +
  • [8] Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015
    Crowson, Cynthia S.
    Matteson, Eric L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) : 253 - 256
  • [9] Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis
    Muratore, F.
    Pipitone, N.
    Hunder, G. G.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S86 - S92
  • [10] Managing of giant cell arteritis and polymyalgia rheumatica
    Gonzalez-Gay, Miguel A.
    Castaneda, Santos
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11): : 1133 - 1144